Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma

Hepatology Research

Volumn 42, Issue 4, 2012, Pages 394-400

  Hagiwara, Satoru ^a   Kudo, Masatoshi ^a   Chung, Hobyung ^a   Ueshima, Kazuomi ^a   Inoue, Tatsuo ^a   Haji, Seiji ^a   Watanabe, Tomohiro ^b   Park, Ah Mee ^a   Munakata, Hiroshi ^a   Sakurai, Toshiharu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

C Jun; C Jun N terminal kinase; Hepatocellular carcinoma; Mitogen activated protein kinases; Postoperative recurrence

Indexed keywords

STRESS ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL;

EID: 84863339267     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00932.x     Document Type: Article

References (18)

1. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.
2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
3. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
5. Hoshida Y, Ikeda K, Kobayashi M etal. Chronic liver disease in the extremely elderly of 80years or more: clinical characteristics, prognosis and patient survival analysis. J Hepatol 1999; 31: 860-6.
6. Ikeda K, Saitoh S, Suzuki Y etal. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
7. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
8. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-90.
9. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
10. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006; 103: 10544-51.
11. Hui L, Bakiri L, Mairhorfer A etal. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007; 39: 741-9.
12. Sakurai T, He G, Matsuzawa A etal. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008; 14: 156-65.
13. Eferl R, Ricci R, Kenner L etal. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003; 112: 181-92.
14. Schwabe RF, Bradham CA, Uehara T etal. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 2003; 37: 824-32.
15. Imamura H, Matsuyama Y, Tanaka E etal. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-7.
16. Portolani N, Coniglio A, Ghidoni S etal. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-35.
17. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-12.
18. Schmitz KJ, Wohlschlaeger J, Lang H etal. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008; 48: 83-90.